Healthcare Services

Major Depressive Disorder Market Outlook Assessing Future Opportunities And Growth Prospects

June 1, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

By 2030, How Much Growth In Market Size Is Expected For The Major Depressive Disorder Market?

The major depressive disorder market size has shown steady growth in recent years. It is projected to increase from $6.26 billion in 2025 to $6.44 billion in 2026, achieving a compound annual growth rate (CAGR) of 2.9%. The expansion observed during the historic period can be linked to factors such as an escalating prevalence of depressive disorders, increasing societal recognition of mental health issues, enhanced availability of antidepressant medications, the broadening of psychiatric care infrastructure, and refined diagnostic guidelines for mood disorders.

The market for major depressive disorder is anticipated to experience consistent expansion over the upcoming years. By 2030, this market is projected to reach $7.49 billion, demonstrating a compound annual growth rate (CAGR) of 3.9%. This anticipated growth throughout the forecast period stems from factors such as an escalating mental health burden linked to lifestyle stress, wider embrace of digital mental health platforms, increased call for tailored depression treatments, broader insurance coverage for mental health services, and ongoing advancements in neuromodulation therapies. Key trends during this period are expected to encompass the increasing use of combination therapy strategies, a heightened need for non-invasive brain stimulation interventions, improved awareness and detection of depression, the expansion of telepsychiatry and remote mental health provisions, and a growing acceptance of innovative and fast-acting antidepressants.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13042&type=smp

Which Significant Factors Are Encouraging Growth In The Major Depressive Disorder Market?

The major depressive disorder market is anticipated to expand due to an increase in cases of substance and alcohol abuse. These terms characterize patterns of excessive and detrimental consumption of various substances, including alcohol, which can result in adverse physical, psychological, and social outcomes. This abuse frequently occurs alongside major depressive disorder, with both conditions often exacerbating each other and substantially elevating the danger of physical and mental damage. For example, in July 2024, a survey from the Substance Abuse and Mental Health Services Administration, a US-based department of health and human services, indicated that 3.1% of people (8.9 million) engaged in opioid misuse in 2023, and 21.8% of individuals aged 12 or older used marijuana, establishing it as the most widely used illicit drug. Furthermore, 9.4% of individuals aged 12 or older had vaped nicotine in the preceding month, an increase from 8.3% recorded in 2022. Consequently, the growing number of substance and alcohol abuse incidents is propelling the major depressive disorder market.

How Are Different Segment Groups Identified Within The Major Depressive Disorder Market?

The major depressive disorder market covered in this report is segmented –

1) By Treatment: Psychotherapy, Medications, Electroconvulsive Therapy (ECT), Transcranial Magnetic Stimulation (TMS), Other Treatments

2) By Diagnosis: Psychiatric Evaluations, Diagnostic And Statistical Manual of Mental Disorders (DSM-5)

3) By End-User: Clinics, Hospitals, Other End-Users

Subsegments:

1) By Psychotherapy: Cognitive Behavioral Therapy (CBT), Interpersonal Therapy (IPT), Dialectical Behavior Therapy (DBT), Psychodynamic Therapy

2) By Medications: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs), Tricyclic Antidepressants (TCAs), Monoamine Oxidase Inhibitors (MAOIs), Atypical Antidepressants

3) By Electroconvulsive Therapy (ECT): Unilateral ECT, Bilateral ECT, Modified ECT

4) By Transcranial Magnetic Stimulation (TMS): Repetitive Transcranial Magnetic Stimulation (rTMS), Deep Transcranial Magnetic Stimulation (dTMS), Theta Burst Stimulation (TBS), Navigated Brain Stimulation (nTMS)

5) By Other Treatments: Cognitive Behavioral Therapy (CBT), Psychodynamic Therapy, Interpersonal Therapy (IPT), Vagus Nerve Stimulation (VNS), Ketamine Therapy, Bright Light Therapy, Psychedelic-Assisted Therapy, Medication (Antidepressants)

Which Trends Are Expected To Shape The Major Depressive Disorder Market?

Major companies operating in the major depressive disorder (MDD) market are prioritizing the development of innovative solutions, such as prescription digital therapeutics (PDTs), to address the increasing need for accessible, evidence-based psychotherapy, supplementary treatments for those with partial responses, and remote, data-driven care options. Prescription digital therapeutics are software-as-medical-device interventions administered via prescription, integrating clinically validated therapeutic content, remote engagement and adherence tools, and data capture capabilities for clinicians; distinct from traditional antidepressant medications or in-person psychotherapy, PDTs offer repeatable, standardized, and remotely supervised behavioral interventions that can complement pharmacotherapy or fill service gaps where provider access is limited. For example, in April 2024, Japan-based Otsuka Pharmaceutical Co., in collaboration with Click Therapeutics, launched Rejoyn (developed as CT-152), a prescription digital therapeutic authorized by the U.S. FDA as an adjunctive treatment for adults with MDD who are already receiving antidepressant medication. Rejoyn is a six-week, smartphone-delivered program built around clinically validated cognitive-emotional brain-training exercises (the Emotional Faces Memory Task/EFMT) and concise therapeutic lessons designed to improve the cognitive control of emotion. The application operates through prescribed delivery, allowing patients to download and complete scheduled sessions on their smartphones while clinicians prescribe and monitor usage, and it was evaluated in the MIRAI randomised, sham-controlled trial, which demonstrated symptom improvement compared to the control group. Its distinguishing characteristics include its neuromodulatory design aimed at neural networks involved in emotion processing, remote, personalized reminders to enhance adherence, and its regulatory clearance as a medical device rather than a general wellness application.

Who Are The Key Market Participants In The Major Depressive Disorder Market?

Major companies operating in the major depressive disorder market are Pfizer Inc., Janssen Research and Development LLC, Merck and Co. Inc., Novartis AG, Sanofi-Aventis US LLC, Bristol Myers Squibb Co., AstraZeneca plc, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Biogen Inc., Otsuka Pharmaceuticals Co. Ltd., Forest Laboratories Inc., H. Lundbeck A/S, Richter Gedeon plc, Allergan plc, Neurocrine Biosciences Inc., BlackThorn Therapeutics Inc., Intra-Cellular Therapies Inc., Axsome Therapeutics Inc., Luye Pharma Group, BrainsWay Ltd., Neumora Therapeutics Inc., Chase Therapeutics Corporation, SAGE Therapeutics Inc., Relmada Therapeutics Inc., Fabre-Kramer Pharmaceuticals Inc., Vistagen Therapeutics Inc.

Access The Complete Major Depressive Disorder Market Report:

https://www.thebusinessresearchcompany.com/report/major-depressive-disorder-global-market-report

Which Geographic Region Represents The Largest Major Depressive Disorder Market Share?

North America was the largest region in the major depressive disorder market in 2025. The regions covered in the major depressive disorder market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Major Depressive Disorder Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/customise?id=13042&type=smp

Browse Through More Reports Similar to the Global Major Depressive Disorder Market 2026, By The Business Research Company

E Pharmacy Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/e-pharmacy-global-market-report

Digital Pharmacy Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/digital-pharmacy-global-market-report

Pharmacy Management System Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/pharmacy-management-system-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795